{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:11:20Z","timestamp":1778735480152,"version":"3.51.4"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Optimal radioactive iodine (RAI) dosing for Graves\u2019 disease remains controversial. Conventional calculated regimens require radioactive iodine uptake (RAIU) testing, whereas empiric fixed-dose strategies risk under- or overtreatment. Although activity per gram of thyroid tissue provides an uptake-independent approach, volume-specific minimum effective doses and functional outcomes remain insufficiently defined. This study aimed to determine the minimum RAI activity per gram required to achieve \u226575% remission across stratified thyroid volumes, to identify the activity associated with the highest euthyroid remission, and to evaluate whether dose escalation increases treatment-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 236 patients with Graves\u2019 disease who received initial single-dose RAI therapy between August 2022 and August 2024 at a tertiary center in Thailand. Thyroid volume by ultrasonography was categorized as &amp;lt;25\u00a0g, 25\u201349.9 g, 50\u201374.9 g, and \u226575 g. Administered activity was grouped as &amp;lt;0.30, 0.30\u20130.39, 0.40\u20130.49, 0.50\u20130.59, and \u22650.60 mCi\/g. Outcomes and adverse events were assessed at 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>The minimum activity required to achieve \u226575% remission increased with thyroid volume: 0.30\u20130.39 mCi\/g for &amp;lt;25\u00a0g glands (90%), 0.40\u20130.49 mCi\/g for 25\u201349.9 g (77%), and 0.50\u20130.59 mCi\/g for 50\u201374.9 g (100%). No activity achieved \u226575% remission in glands \u226575 g, with a maximum rate of 45%. Across all volumes, the highest euthyroid rates occurred at the lowest effective activity, whereas dose escalation increased hypothyroidism without improving overall remission. Adverse events were infrequent (5.5\u20137.6%) and mostly mild. Moderate neck pain was more frequent at higher activities, with a strong positive correlation between administered activity and total adverse events (r = 0.82, p = 0.089).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates that volume\u2212stratified radioiodine dosing offers an effective and practical alternative to traditional 24\u2212hour RAIU\u2013based dosimetry for Graves\u2019 disease. Adjusting activity according to thyroid volume yields predictable remission while avoiding the logistical burdens of uptake testing. The dose\u2013response relationship also underscores the need to balance efficacy with avoidance of excess toxicity. Overall, this individualized, volume\u2212based strategy provides a scalable and efficient framework for optimizing radioiodine therapy, particularly in resource\u2212limited settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1823030","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:30:03Z","timestamp":1778733003000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Preliminary volume\u2212based optimization of radioactive iodine dose without radioactive iodine uptake in Graves\u2019 disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Keattichai","family":"Keeratitanont","sequence":"first","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Burapha University","place":["Chonburi, Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sornsupha","family":"Limchareon","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Burapha University","place":["Chonburi, Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sutasinee","family":"Kongpromsuk","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Burapha University","place":["Chonburi, Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Watanya","family":"Jaidee","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Burapha University","place":["Chonburi, Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teetawat","family":"Jearsirikul","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Burapha University","place":["Chonburi, Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantham","family":"Sunmahakhun","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Burapha University","place":["Chonburi, Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association guideline for the management of Graves\u2019 hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06274-5","article-title":"The EANM guideline on radioiodine therapy of benign thyroid disease","volume":"50","author":"Campenn\u00ec","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.139222","article-title":"Comparison of clinical outcome after a fixed dose versus dosimetry-based radioiodine treatment of Graves\u2019 disease: Results of a randomized controlled trial in Indian population","volume":"18","author":"Jaiswal","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2016.31.1.168","article-title":"Comparison of fixed versus calculated activity of radioiodine for the treatment of Graves disease in adults","volume":"31","author":"Canto","year":"2016","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-021-02767-0","article-title":"Clinical efficacy of fixed-dose radioactive iodine for the treatment of hyperthyroidism at a single centre: our experience","volume":"191","author":"Nair","year":"2022","journal-title":"Ir J Med Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28316","article-title":"Cure rates after a single dose of radioactive iodine to treat hyperthyroidism: The fixed-dose regimen","volume":"14","author":"Madu","year":"2022","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jrras.2023.100633","article-title":"Evaluating the effectiveness of a fixed little dose of radioactive iodine (I131) in treatment for Graves\u2019 disease","volume":"16","author":"Al-Qahtani","year":"2023","journal-title":"J Radiat Res Appl Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12902-024-01588-3","article-title":"Prospective study to evaluate radioactive iodine of 20 mCi vs 10\u201315 mCi in Graves\u2019 disease","volume":"24","author":"Kanokwongnuwat","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83812","article-title":"Outcomes of fixed-dose radioactive iodine therapy in hyperthyroidism and optimization of follow-up after treatment failure with low-dose antithyroid medication","volume":"17","author":"Kantikool","year":"2025","journal-title":"Cureus"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.01.010","article-title":"Radioactive iodine therapy of Graves\u2019 disease in patients pretreated with methimazole without radioiodine uptake for dose estimation","volume":"30","author":"Mihailescu","year":"2024","journal-title":"Endocr Pract"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000002045","article-title":"Predictive factors for the efficacy of radioiodine therapy in patients with Graves\u2019 disease","volume":"46","author":"Iwanaga","year":"2025","journal-title":"Nucl Med Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.20945\/2359-4292-2025-0159","article-title":"Radioactive iodine therapy outcomes in young adults with Graves disease: a bi-center observational study","volume":"69","author":"Liu","year":"2025","journal-title":"Arch Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/BF02093716","article-title":"Determination of thyroid volume by ultrasound from the neonatal period to late adolescence","volume":"150","author":"Chanoine","year":"1991","journal-title":"Eur J Pediatr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2020.329","article-title":"A new simple, personalized, and quantitative empirical method for determining 131I activity in treating Graves\u2019 disease","volume":"16","author":"Xu","year":"2020","journal-title":"Acta Endocrinol (Buchar)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40842-018-0071-6","article-title":"Efficacy of radioactive iodine treatment of graves\u2019 hyperthyroidism using a single calculated 131I dose","volume":"4","author":"Wong","year":"2018","journal-title":"Clin Diabetes Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01339-w","article-title":"Success rate of radioactive iodine treatment for children and adolescent with hyperthyroidism","volume":"44","author":"Namwongprom","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"31063","DOI":"10.1038\/s41598-024-82052-z","article-title":"A Belgian single centre outcome study of radioiodine treatment in adolescents with Graves\u2019 disease","volume":"14","author":"Chielens","year":"2024","journal-title":"Sci Rep"},{"key":"B19","article-title":"Health inequalities in Thailand: geographic distribution of medical supplies in the provinces","volume":"35","author":"Nishiura","year":"2004","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07678-1","article-title":"Theranostics and nuclear medicine practice in Asia-Pacific: an IAEA regional study","volume":"53","author":"Al-Ibraheem","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2385-1-1","article-title":"A mathematical model of optimized radioiodine-131 therapy of Graves\u2019 hyperthyroidism","volume":"1","author":"Doi","year":"2001","journal-title":"BMC Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2020039","article-title":"Severe radiation thyroiditis after radioactive iodine for treatment of Graves\u2019 disease","volume":"62","author":"Tay","year":"2021","journal-title":"Singapore Med J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199206253262603","article-title":"Occurrence of ophthalmopathy after treatment for Graves\u2019 hyperthyroidism","volume":"326","author":"Tallstedt","year":"1992","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13061404","article-title":"The impact of radioiodine (131I) therapy of thyroid disease on salivary glands function and inflammation: a comprehensive review","volume":"13","author":"Bellini","year":"2025","journal-title":"Biomedicines"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1823030\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:30:05Z","timestamp":1778733005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1823030\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":24,"alternative-id":["10.3389\/fendo.2026.1823030"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1823030","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1823030"}}